Cellectis (CLLS) Current Deferred Tax Assets (2024)

Cellectis' (CLLS) quarterly Current Deferred Tax Assets came in at $710000.0 in Q2 2024, up 73.59% quarter-over-quarter from $409000.0 in Q1 2024.

Cellectis (CLLS) Current Deferred Tax Assets (2024) Analysis & Trends

Cellectis' Current Deferred Tax Assets history runs 1 years deep, the most recent figure standing at $710000.0 for Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Cellectis	281.48 Mn	95.81 Mn	-

Download Data